Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
|
|
- Catherine Blair
- 5 years ago
- Views:
Transcription
1 Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
2 Outline Case study Introduction of Current management of infantile leukemia New treatment strategies of infantile leukemia Prognostic outcomes of infantile leukemia Conclusion
3 Case study: Part I Thai F 1+mo presented with red spots at buttock. PE: afebrile, petechial rash, erythematous plaques at scalp and buttock with hepatosplenomegaly. CBC: Hb 9.8 g/dl, WBC 244,410/cu.mm. (N 2, L 1, blast 98%), platelet 19,000/cu.mm. BMA: lymphoblast 85% with positive for CD19, PAX5, CD34, TdT, HLA-DR with aberrant expression of CD33 Cytogenetics: 46, XX, t(4;11)(q21;q23) [30] Multiplex RT-PCR: positive for MLL/AF4 Diagnosis: MLL rearranged infantile ALL Unpublished data; courtesy of Division of Pediatric Hematology-Oncology, Ramathibodi.
4 Case study: Part I Which plan of management should be proposed for this infant? A. Chemotherapy alone B. HSCT after first CR C. HSCT when relapse
5 Definition: Leukemia (ALL and AML) in infants diagnosed before one year of age Leukemia in infants has unique epidemiological, biological, and clinical characteristics Biondi A, et al. Blood. 2000;96: Silverman LB. Pediatr Blood Cancer. 2007;49 (7 Suppl):
6 Incidence: US: cases per million live births (approx.160 cases per year with ALL:AML = 1.3:1) Thailand (ThaiPOG): 82 case (ALL 42 cases [51%]; AML 35 cases [43%]) during Infantile ALL approx. 2.5% to 5% of pediatric ALL Infantile AML comprises 6% to 14% of pediatric AML Wiangnon S, et al. Asian Pac J Cancer Prev. 2011;12(9): SEER Cancer Statistics Review, , National Cancer Institute. Bethesda, MD.
7 Pathogenesis: Prenatal origin and chemical exposure in mother Few studies found an increased risk of infantile leukemia after in utero exposure to household pesticides, dipyrone, bioflavonoids, estrogens which might be due to genotoxic effects to fetus was associated with the mixed lineage leukemia (MLL) gene fusion, likely as a result of topoisomerase II inhibition Hernández AF, et al. Int J Mol Sci. 2016;17(461):1-16.;
8 Characteristics: Presentations tend to be more aggressive: hepatosplenomegaly, extramedullary involvement (i.e. skin; leukemia cutis), CNS involvement, hyperleucocytosis Infants with ALL have a particularly high risk of treatment failure and early relapse Biondi A, et al. Blood. 2000;96: Silverman LB. Pediatr Blood Cancer. 2007;49 (7 Suppl):
9 Diagnosis: by clinical and bone marrow studies Blast morphology and flow cytometry: Infantile ALL-mostly pre B-cell phenotype with aberrant co-expression of myeloid markers Lymphoblasts from infants with MLL rearrangements (MLL-r) are often CD10 negative and express high levels of FLT3 Infantile AML-mostly FAB M4/M5 and M7 Biondi A, et al. Blood. 2000;96: Silverman LB. Pediatr Blood Cancer. 2007;49 (7 Suppl): Masetti R, et al. Front Pediatr. 2015;3:37.
10 Diagnosis: Cytogenetics and molecular genetics: Chromosomal and molecular aberrations of leukemia in infants are markedly different from those in children Another distinctive trait of infantile leukemia is the low frequency of favorable cytogenetic and molecular features Infantile ALL rarely found ETV6/RUNX1; ALL with MLL-r commonly found overexpression of FLT3 Infantile AML rarely found NPM1 or CEBPA mutations; And, FLT3-ITD mutation is significantly lower in infantile AML Biondi A, et al. Blood. 2000;96: Masetti R, et al. Front Pediatr. 2015;3:37.
11 Diagnosis: Cytogenetics and molecular genetics: Balanced chromosomal translocations involving 11q23 or MLL-r (MLL1 or KMT2A rearrangements) are found in 70-80% of infantile ALL and 35-50% of infantile AML** Infantile ALL mostly found MLL-AF4 (KMT2A-AFF1); t (4;11)(q21;q23) Infantile AML mostly found MLL-AF9; t(9;11)(p23;q23) and MLL-AF10; t(10;11)(p12;q23) **MLL-r have also been reported with increased frequency in mixed phenotypic leukemias and therapy-related leukemias after topoisomerase II inhibitor therapy Winters AC, Bernt KM. Front Pediatr. 2017;5:4.
12 Winters AC, Bernt KM. Front Pediatr. 2017;5:4.
13 Diagnosis: Cytogenetics and molecular genetics: Detection of MLL (KMT2A)-r might be high variety and not be available in some particular institutes Cytogenetics* Fluorescence in situ hybridization (FISH)* Southern blot Long-distance inverse (LDI) PCR Multiplex PCR for MLL-AF4 (KMT2A-AFF1)** Next-Gen sequencing
14 Management Treatment for infantile AML: not different from older children Treatment for infantile ALL: Chemotherapy HSCT New treatment strategies (e.g. epigenetic targeted therapy, immunotherapy)
15 Management for infantile ALL Intensive chemotherapy regimens: Using agents not typically incorporated into frontline therapy for older children with ALL Postinduction intensification courses with high doses of cytarabine and methotrexate Triple IT to prevent CNS relapse Balancing between Intensity, Relapse and Toxicity With current approaches, treatment-related mortality reported up to 10% of infants Hilden JM, et al. Blood. 2006; 108(2): Pieters R, et al. Lancet. 2007;370(9583): Dreyer ZE, et al. Pediatr Blood Cancer. 2015;62(3):
16 Management for infantile ALL The current THREE collaborative clinical trials 1. Children's Oncology Group (COG) 2. Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) 3. Interfant Study Group
17 Kotecha RS, et al. Blood cancer J. 2014;4:e200.
18 Management for infantile ALL:
19 Management for infantile ALL Treatment for ALL infants with MLL-r Treatment for ALL infants without MLL-r New treatment strategies for ALL and AML infants
20 Management for infantile ALL Treatment for ALL infants with MLL-r Intensive chemotherapy 1. Interfant: cytarabine-intensive chemotherapy (lowand high-dose cytarabine) 5-yr EFS 37% 2. COG: multiple doses of high-dose MTX, CTX, Eto 5-yr EFS 37% On COG P9407 (NCT ) trial: shortened (46- week) intensive chemotherapy 5-yr EFS 36% Hilden JM, et al. Blood. 2006; 108(2): Pieters R, et al. Lancet. 2007;370(9583): Dreyer ZE, et al. Pediatr Blood Cancer. 2015;62(3):
21 Management for infantile ALL Treatment for ALL infants with MLL-r HSCT: HSCT in first CR remains controversial!! 1. COG: no difference in EFS between patients underwent HSCT in first CR and received chemotherapy 2. Japanese trial: all infants proceeded to HSCT 3 to 5 months after diagnosis ( ) 3-yr EFS 34% with 27% relapsed before transplant Kato M, et al. Br J Haematol. 2015;168(4): Kosaka Y, et al. Blood. 2004;104(12): Dreyer ZE, et al. J Clin Oncol. 2011;29(2):214-22
22 Management for infantile ALL Treatment for ALL infants with MLL-r HSCT: HSCT in first CR remains controversial!! 3. Interfant-99: no difference in DFS in high-risk infants (defined by prednisone response) with either HSCT in first CR or chemotherapy alone** **In a subset analysis, HSCT in first CR was associated with a significantly better DFS for <6 mo-old infants with MLL-r and had either a poor prednisone response or leukocyte counts >300,000/µL (64% reduction) Pieters R, et al. Lancet. 2007;370(9583): Mann G, et al. Blood. 2010;116(15):
23 Yoshimi A, et al. Pediatr Transplant. 2017;21:e12918.
24 Management for infantile ALL Treatment for ALL infants without MLL-r Intensive chemotherapy 1. COG: P9407 (NCT ) trial 5-yr EFS 70% 2. Interfant-99: cytarabine-intensive treatment regimen 4-yrs EFS 74% 3. Japanese trial: subgroup analysis (n = 22, 91% males) favorable outcome comparable to older children with ALL 5-yr EFS 95.5% Pieters R, et al. Lancet. 2007;370(9583): Dreyer ZE, et al. Pediatr Blood Cancer. 2015;62(3): Tomizawa D, et al. Leukemia. 2007;21(11):
25 MLL fusion protein involved histone modifications and transcription elongations in hematopoiesis **Promoter hypermethylation **Disruption of HOX gene expression Winters AC, Bernt KM. Front Pediatr. 2017;5:4.
26 Management for infantile ALL New treatment strategies for ALL infants FLT3 inhibitors in MLL-r ALL TACL study: phase I trial quizartinib (AC220) in relapsed acute leukemia (status: completed in 2017, unpublished) Midostaurin (PKC412) (NCT ) for relapsed/refractory FLT3-mutated AML and MLL-r ALL (status: terminated due to low No. of participants)
27 Management for infantile ALL New treatment strategies for ALL infants FLT3 inhibitors in MLL-r ALL COG: phase III trial of intensive chemotherapy backbone (AALL0631) +/- Lestaurtinib (CEP-701) (NCT ) for MLL-r ALL (status: completed in 2017, unpublished)
28 Management for infantile ALL New treatment strategies for ALL infants Hypomethylating agents AALL15P1 (NCT ): phase II trial adding azacitidine to the Interfant chemotherapy backbone in MLL-r ALL infants (status: recruiting)
29 Management for infantile ALL New treatment strategies for ALL infants Proteasome and HDAC inhibitors: SJCRH (NCT ): adding bortezomib and vorinostat into backbone regimens for MLL-r hematologic malignancies (status: terminated*) SJCRH (NCT ): phase I/II trial incorporating bortezomib and vorinostat into an ALL chemotherapy backbone (Total therapy for infant ALL I) for newly diagnosed infants with ALL (status: recruiting) *Terminated early, because accrual goals were no longer feasible based on restrictions imposed by DSMB
30 Stackelberg AV, et al. J Clin Oncol. 2016;34(36): Gardner R, et al. Blood. 2016;127: Rayes A, et al. Pediatr Blood Cancer. 2016;63: Management for infantile ALL New treatment strategies for ALL infants Immunotherapy: CD19-directed CAR-T Blinatumomab (bidirectional antibody targeting CD19) **Theoretical concerns about the immaturity of T-cell responses **Relapses with myeloid leukemia after treatment?lineage plasticity of MLL-r blasts
31 Management for infantile ALL MLL specific pathways and targeted inhibitors DOT1L inhibitor NCT : phase I trial of pinometostat (EPZ- 5676) in the treatment of pediatric relapsed/refractory MLL-r Leukemia (status: completed in 2016, unpublished)
32 Management for infantile ALL MLL specific pathways and targeted inhibitors BCL-2 inhibitor NCT : studying the effects of BCL-2 inhibitor, obatoclax in cell samples from patients with infantile AML (status: completed in 2016, unpublished)
33 Prognosis Prognostic factors for infantile AML: unremarkable Poor prognostic factors for infantile ALL: A very young age (<6 mo and poorer in 90 days) Extremely high presenting leukocyte count ( 200, ,000/μL) MLL-r CD10 negativity Poor early response, as reflected by a poor response to a prednisone prophase or high levels of MRD at the end of induction and consolidation phases Hilden JM, et al. Blood. 2006; 108(2): Pieters R, et al. Lancet. 2007;370(9583): Dreyer ZE, et al. Pediatr Blood Cancer. 2015;62(3):
34 ThaiPOG protocol (Updated in 2016)
35
36
37 Pediatric ALL survival in (ThaiPOG-ALL-01-05&-02-05) 5-yr OS 67.2% 5-yr EFS 58.7% Seksarn P, et al. Asian Pac J Cancer Prev. 2015;16(11):
38 Conclusion Leukemia in infants is an infrequent but very challenging disease because of the high rate of toxicities and relapses The outcome of infantile ALL is inferior to the outcome of childhood ALL, whereas infantile AML cure rates are comparable to these of older children Because of the rarity of the disease, the complexity of treatment protocols and clinical management, and the high rate of toxic complications, treatment of these patients should be reserved to experienced sites
39 Conclusion The issue whether HSCT should be largely employed in infants with leukemia in CR1 or rather mainly reserved to relapsing patients remains individualized (beneficial in high-risk status) and needs to be addressed in future For further outcome improvement, particularly in infantile ALL, new treatment modalities (i.e. epigenetic treatment and immunotherapy) should be incorporated into the treatment protocols Long-term follow-up for survivors is crucial to monitor and overcome any long-lasting toxic complications
40 Thank you
Risk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationTherapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328
Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical
More informationTherapy Optimization in Infant Acute Lymphoblastic Leukemia
ICKSH 2018 & 59 th Annual Meeting (March 31, 2018 Seoul - Korea) Therapy Optimization in Infant Acute Lymphoblastic Leukemia Children s Cancer Center, National Center for Child Health and Development Infant
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationAcute Leukemia. Sebastian Giebel. Geneva 03/04/
Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012 www.ebmt.org Acute leukemias: EBMT survey 2 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant 2009 3 Acute leukemias: INCIDENCE
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationA pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH
A pediatric patient with acute leukemia of ambiguous lineage with a NUP98NSD1 rearrangement SH20170203 Rebecca LeemanNeill, Ronald Rice, Anita Malek, Patricia Raciti, Susan Hsiao, Mahesh Mansukhani, Bachir
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationCARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital
CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationHematopathology Case Study
Hematopathology Case Study AMP Outreach Course 2009 AMP Annual Meeting John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine November 19, 2009 HISTORY Case History An
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationTreatment of infant leukemias: challenge and promise
PEDIATRIC HEMATOLOGY:INSIGHTS APPLICABLE TO ALL! Treatment of infant leukemias: challenge and promise Patrick Brown 1 1 Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationFuture Directions in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Future Directions in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Heidi Trinkman, PharmD. Clinical Pharmacy Specialist Cook Children s Medical Center Fort Worth, Texas Disclosures Speaker s
More information«Adverse Prognosis» Acute Myeloid Leukemia
23. Fortbildungskurs Lausanne, 11.11.2017 «Adverse Prognosis» Acute Myeloid Leukemia Markus G. Manz Zentrum für Hämatologie und Onkologie UniversitätsSpital Zürich Content AML Update on current definition
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationAcute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities
Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationTest Name Results Units Bio. Ref. Interval. Positive
Lab No 135091548 Age 35 Years Gender Female 1/9/2017 120000AM 1/9/2017 103420AM 4/9/2017 23753M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE 3 t (1;19)
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationAcute Myeloid Leukemia with RUNX1 and Several Co-mutations
Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year
More informationAcute myeloid leukemia: a comprehensive review and 2016 update
OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More information2011: ALL Pre-HCT. Subsequent Transplant
2011: ALL Pre-HCT The Acute Lymphoblastic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific pre-hct data such as: the recipient s hematologic and cytogenetic
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More informationSingle Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia
Single Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationCase Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute leukemia
Int J Clin Exp Pathol 2014;7(7):4498-4502 www.ijcep.com /ISSN:1936-2625/IJCEP0000851 Case Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute
More informationInitial Diagnostic Workup of Acute Leukemia
Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationBumps on the Neck and Groin of a 2-Year-Old Male. Laboratory Findings: Table 1, Table 2; Figure 1; Image 1, Image 2, Image 3
Bumps on the Neck and Groin of a 2-Year-Old Male 1 Erikakelly Strand, BS* Clinical History Patient: 2-year-old white male. Chief Complaint: Bumps on neck and groin. History of Present Illness: A 2-year-old
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationMRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationCurrent Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review
EXPERT OPINION Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review Chi-Kong Li Department of Pediatrics, Prince of Wales Hospital, The Chinese University
More information7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, Eva Lengfelder
Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines - A prospective multicenter
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationPediatric Acute Lymphoblastic Leukemia. Highlights of ASH 2015
Pediatric Acute Lymphoblastic Leukemia Highlights of ASH 2015 Thai National Protocol Outcomes Outcome is very dependent on treatment Patient s compliance Treatment of ALL Induction Intensification Maintenance
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationThe probability of curing children with acute. brief report
brief report Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) Khadra
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationKeywords: Acute Myeloid Leukemia, FLT3-ITD Mutation, FAB Subgroups, Cytogenetic Risk Groups
Original Articleeee fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007-2008 Emami AH, 1 Shekarriz
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 8 COG-AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like
More informationGenomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT?
Genomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT? Matt McKinney MD Instructor in Medicine, Division of Hematologic Malignancies, Department of Medicine Duke University
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationFluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)
PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationACUTE LEUKEMIA. Zwi N. Berneman University of Antwerp & Antwerp University Hospital. 16th Post-ASH Meeting Zaventem, 10 January 2014
ACUTE LEUKEMIA Zwi N. Berneman University of Antwerp & Antwerp University Hospital 16th Post-ASH Meeting Zaventem, 10 January 2014 ACUTE MYELOID LEUKEMIA HIGH-RISK AML Clinically and biologically distinct
More information